The Importance of Quality in Our Medicines (2of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 19:09 4 years ago 267 Скачать Далее
Policy Initiatives for Pharmaceutical Quality (5of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 19:34 4 years ago 121 Скачать Далее
Continuous Manufacturing of Drug Product (20of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 26:11 4 years ago 3 696 Скачать Далее
Quality Metrics, Quality Culture, and Data-Driven Decisions (16of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 20:57 4 years ago 959 Скачать Далее
Pharmaceutical Quality Surveillance Program (14of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 22:17 4 years ago 227 Скачать Далее
Keynote: CDER’s Commitment to Pharmaceutical Quality (1of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 16:13 4 years ago 607 Скачать Далее
The Importance of Quality in Our Medicines (2of28) Generic Drugs Forum – Apr. 3-4, 2019 U.S. Food and Drug Administration 27:53 4 years ago 384 Скачать Далее
Quality-Related Compliance Actions and Trends (15of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 20:08 4 years ago 181 Скачать Далее
Case Studies: Continuous Manufacturing of Drug Substance (21of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 18:17 4 years ago 952 Скачать Далее
Policy Considerations for Continuous Manufacturing (19of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 20:53 4 years ago 392 Скачать Далее
Application Manufacturing Assessment (4of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 26:22 4 years ago 228 Скачать Далее
FDA’s Quality Assessment and Knowledge Management - KASA (11of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 23:35 4 years ago 3 422 Скачать Далее
Quality Assessment of BLAs, NDAs, and ANDAs (3of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 25:06 4 years ago 631 Скачать Далее
Data Quality Expectations for Biosimilars with Case Studies (29of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 16:06 4 years ago 847 Скачать Далее
FDA Perspectives on Biosimilar BLA-Manufacturing (28of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 24:48 4 years ago 2 023 Скачать Далее
Small Molecule Case Studies (8of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 26:41 4 years ago 398 Скачать Далее
Panel Questions and Discussion (10of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 20:50 4 years ago 105 Скачать Далее
Panel Questions and Discussion (13of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 16:10 4 years ago 321 Скачать Далее
Panel Questions and Discussion (17of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 9:09 4 years ago 135 Скачать Далее
End-to-end Integrated Continuous Manufacturing (25of33) Quality – Oct. 16-17, 2019 U.S. Food and Drug Administration 20:18 4 years ago 199 Скачать Далее
